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Box 1 Pathophysiology of lactose 
malabsorption
 ► Lactose malabsorption is typically caused by 
lactase downregulation after infancy due to 
lactase non-persistence which in Caucasians is 
mediated by the LCT −13’910:C/C genotype.
 ► Lactase non-persistence is the genetic wildtype 
and not a disease. Both lactase persistence and 
non-persistence are common phenotypes in 
healthy humans.
 ► The lactase genetic region is among the genetic 
regions strongest shaped by human evolution 
within the last 10 000 years, with lactase 
persistence providing a selective advantage of 
up to 4%–5% per generation.
 ► The LCT −13’910 is the region within the 
human genome with the strongest interaction 
with the intestinal microbiota. The LCT 
−13’910:C/C genotype is associated with higher 
Bifidobacteria levels on lactose consumption 
(bifidogenic effect).
 ► Genetic and physiological studies suggest 
higher bone mineral density and larger height 
in individuals with lactase persistence.
SummaRy
Lactose is the main source of calories in milk, an essential 
nutriedigestion, patients with visceral hypersensitivity 
nt in infancy and a key part of the diet in populations 
that maintain the ability to digest this disaccharide in 
adulthood. Lactase deficiency (LD) is the failure to express 
the enzyme that hydrolyses lactose into galactose and 
glucose in the small intestine. The genetic mechanism of 
lactase persistence in adult Caucasians is mediated by 
a single C→T nucleotide polymorphism at the LCTbo 
−13’910 locus on chromosome-2. Lactose malabsorption 
(LM) refers to any cause of failure to digest and/or absorb 
lactose in the small intestine. This includes primary 
genetic and also secondary LD due to infection or other 
conditions that affect the mucosal integrity of the small 
bowel. Lactose intolerance (LI) is defined as the onset of 
abdominal symptoms such as abdominal pain, bloating and 
diarrhoea after lactose ingestion by an individual with LM. 
The likelihood of LI depends on the lactose dose, lactase 
expression and the intestinal microbiome. Independent of 
lactose digestion, patients with visceral hypersensitivity 
associated with anxiety or the Irritable Bowel Syndrome 
(IBS) are at increased risk of the condition. Diagnostic 
investigations available to diagnose LM and LI include 
genetic, endoscopic and physiological tests. The association 
between self-reported LI, objective findings and clinical 
outcome of dietary intervention is variable. Treatment of LI 
can include low-lactose diet, lactase supplementation and, 
potentially, colonic adaptation by prebiotics. The clinical 
outcome of these treatments is modest, because lactose 
is just one of a number of poorly absorbed carbohydrates 
which can cause symptoms by similar mechanisms.
InTRoduCTIon
Lactose metabolism continuous to fascinate 
anthropologists, geneticists, physiologists and 
clinicians.1–3 Studying the mechanisms of lactose 
digestion and intolerance has provided insights 
not only into dietary causes of functional intes-
tinal symptoms but also into human evolution 
and nutrition, culture and lifestyle (box 1). 
Recent evidence has demonstrated the impact 
of lactose digestion on the human microbiota 
and general health. Considering these issues 
has raised possible concerns of a dairy-free diet. 
This review will emphasise recent developments 
in the clinical diagnosis and management of this 
condition (box 2).
LaCToSe IS The maIn SugaR In mILk
Milk production by the mammary gland is a 
defining feature of mammals and lactose (‘milk 
sugar’; β-galactosyl-1,4 glucose) is the main 
source of carbohydrate in human milk and that of 
other mammals, except for sea lions and walruses 
which produce low volume, viscous and fatty 
lactose-free milk.4
Infants are uniquely adapted to lactose-based 
nutrition. In a randomised controlled study, 
infants fed with breast milk or lactose-based 
formula had higher levels of glucose and other 
nutrients (eg, amino acids) in the blood compared 
with infants with lactose-free formula.5 Lactose 
also seems to be the only monosaccharide or 
disaccharide that does not increase the risk of 
dental caries.6 In adults, dairy products account 
for approximately 14% of energy intake in 
Europe and North America. In recent years, the 
amount of milk consumed has slightly decreased 
in these regions. By contrast, in China and many 
developing countries, milk intake contributes only 
4% to energy intake; however, consumption is 
increasing rapidly.3
Cow’s milk contains approximately 5 g lactose 
per 100 mL, equating to 12.5 g lactose in a typical 
serving size of 250 mL. Lactose is also present 
in cultured milk products such as yoghurt and 
cheese (the second-largest fermentation industry 
after alcohol).3 Yoghurt contains ≈50% of the 
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Box 2 Clinical relevance of lactose intolerance
 ► Lactose intolerance is defined as symptoms on lactose 
exposure in individuals with lactose malabsorption.
 ► Most individuals with lactose malabsorption tolerate a dose 
of at least 12 g lactose (corresponding to 250 mL of milk) 
without problems. Larger doses may be tolerated if consumed 
with food or spread over a whole day.
 ► Symptoms of lactose intolerance depend on the strength of 
the stimulus (ie, lactose dose) and the presence of visceral 
hypersensitivity, as observed in many patients with IBS.
 ► Treatment options for lactose intolerance include a low-
lactose diet, oral lactase enzyme replacement, prebiotics 
that produce bacterial lactase in the colon and, potentially, 
prebiotics that adapt the colonic microbiota.
 ► Intolerance of low–moderate lactose doses often indicates 
the presence of IBS. Such individuals are sensitive to a range 
of poorly absorbed, fermentable foods (‘FODMAPs’). Effective 
dietary treatment in this group requires not a low-lactose but 
a low-FODMAP diet.
FODMAP, fermentable oligosaccharide, disaccharide 
and monosaccharide and polyols.FODMAP, fermentable 
oligosaccharide, disaccharide and monosaccharide and polyols.
Table 1 Lactose content in dairy products and foods (representative values are provided)
Food
Lactose content (g) per 
100 g
Lactose content per typical 
serving (g)
Milk (full) 4.7 15
Milk (skimmed) 4.8 15
Lactose-free milk <0.1 <0.1
Goat’s milk 4.5 13
Buttermilk 3.0 9.0
Butter 0.5 0.1
Yoghurt (fresh) 3.0 9.3
Yoghurt (biological) 4.0 9.5
Cream cheese 3.0 0.9
Soft cheese (eg, camembert) 0.3 0.1
Hard cheese (eg, cheddar and 
gruyere)
0.1 <0.1
Cream 3.6 3.2
Soft ice cream 6.4 5.7
Latte Macchiato 4.3 8.6
Lasagne 1.1 2.6
Cheeseburger 0.9 1.1
Ready sauces 3.6 4.5
Pudding/custard 3.6 4.5
Rice, nut, soy or oat beverages 0.0 0.0
Meat and alternatives contain very little lactose. Products that may include lactose are those 
prepared with milk or milk products such as some processed meat, sausage, breaded or battered 
meat or fish, commercial egg substitutes, scrambled eggs, soufflés.
Fats and oils contain very little lactose. Products that may include lactose are those prepared with 
milk or milk products such as butter or margarine made with milk or whey powder and salad 
dressings (eg, ranch style or buttermilk).
Prepared foods may include lactose when made with milk or milk products. These include store 
bought gravy or sauce mixes, vegetable or chip dips, soups, chips or snack crackers (eg, cheese 
flavoured), artificial whipped toppings, powdered meal replacement supplements and cream-
based liqueurs.
lactose of unprocessed milk; whereas, cheese has low lactose 
content, especially if long-ripened products are consumed.3 
Additionally, lactose powder is also a common additive in 
typical processed foods, enhancing the texture and flavour of 
sausages, gravy, margarines, bread, sauces, and many prepared 
meals (table 1).
LaCToSe dIgeSTIon and aBSoRPTIon
Digestion and absorption of lactose takes place in the small intes-
tine (figure 1).7 8 Lactose is the main substrate of lactase-phlorizin 
hydrolase expressed on the brush border of villi with its highest 
expression in the mid-jejunum. The enzyme spans the apical 
membrane of mature enterocytes and is made up of two identical 
extracellular 160 kDa polypeptide chains, as well as a short intra-
cytoplasmic part. The alpha-glucosidase activity of this enzyme 
cleaves the milk sugar disaccharide into the monosaccharides 
glucose and galactose which are then actively transported into 
epithelial cells (enterocytes) by the sodium(+)/glucose (galactose) 
co-transporter (SGLT1). At higher concentrations, a second facil-
itative transporter (GLUT2) becomes involved.9 From the entero-
cytes, glucose moves into the surrounding capillaries by facilitated 
diffusion.
LaCTaSe deFICIenCy and LaCToSe maLaBSoRPTIon
The terms relating to lactose metabolism are often mixed-up 
which may cause confusion (table 2). Lactase deficiency (LD) 
is the failure to express lactase at the brush border of the small 
intestine. Lactose malabsorption (LM) refers to any cause of 
failure to digest and/
or absorb lactose in the 
small intestine. Lactose 
intolerance (LI) is the 
occurrence of symp-
toms such as abdominal 
pain, bloating or diar-
rhoea in LM patients 
after ingestion of 
lactose.
Congenital lactase 
deficiency is a very 
rare paediatric condi-
tion that causes severe 
symptoms and failure to 
thrive in infants.10 The 
most common cause 
of LM in adolescents 
and adults is primary 
(genetic) lactase 
non-persistence (LNP). 
The activity of lactase 
in the small intestine 
reaches a peak at the 
time of birth but is 
reduced in most popu-
lations during child-
hood, a process which 
is thought to facilitate 
weaning. However, 
in some individuals, 
high activity of lactase 
persists, enabling 
consumption of large 
amounts of lactose also 
in adulthood. It should 
be emphasised that, worldwide, most individuals have LNP with 
phenotypic LD and LM (figure 2). Thus, LNP, LD and LM are 
not diseases but normal variants of human metabolism.11 Other 
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Table 2 Glossary with definitions related to lactase deficiency, lactose malabsorption and lactose intolerance
Concept definition
Congenital lactase deficiency CLD Very rare genetic disorder (typically frameshift mutations) leading to lack of expression of lactase and severe symptoms 
immediately after birth
Lactase non-persistence LNP Decrease of intestinal lactase expression in the first two decades of life. Phenotype in most individuals worldwide 
(biological wildtype)
Lactase persistence LP Continued expression of intestinal lactase expression beyond infancy; dominant phenotype in Western countries.
Lactase deficiency LD Inability to digest large amounts of lactose due to low lactase expression in the small intestine
Lactose malabsorption LM Passage of lactose into the large intestine as a consequence of LD or other pathology (eg, rapid transit)
Primary lactose malabsorption Lactose malabsorption due to lactase non-persistence (dominant phenotype worldwide).
Secondary lactose malabsorption Lactose malabsorption due to lower lactase expression, typically in the setting of intestinal inflammation (may be 
reversible).
Lactose intolerance LI Appearance of typical intestinal symptoms such as abdominal pain, bloating, diarrhoea in individuals with LM after lactose 
ingestion determined by appropriate testing (ideally blinded testing).
Functional lactose intolerance Symptoms of LI on lactose challenge in individuals without lactose malabsorption.
Self-reported lactose intolerance SLI History of LI symptoms without formal testing of either LM or LI.
Figure 1 Physiology of lactose malabsorption. SCFA, short chain fatty acids.
causes of LM include secondary (acquired) LD, rapid small intes-
tinal transit and small bowel bacterial overgrowth.
In case of LM (primary or secondary), undigested lactose comes 
into contact with the intestinal microbiota. Bacterial fermenta-
tion of lactose results in production of gasses including hydrogen 
(H2), carbon dioxide (CO2), methane (CH4) and short chain fatty 
acids (SCFA) that have effects on GI function (figure 1).
LaCToSe InToLeRanCe
Lactose malabsorption (LM) is a necessary precondition for 
lactose intolerance (LI). However, the two must not be confused 
and the causes of symptoms must be considered separately. 
Many individuals with LM have no symptoms after ingestion 
of a standard serving of dairy products (table 1) whereas others 
develop symptoms (‘intolerance’) such as abdominal pain, 
borborygmi (rumbling tummy) and bloating after lactose intake 
(figure 1). The onset of these symptoms is strongly correlated to 
the appearance of hydrogen gas during breath tests12 . Further, 
undigested lactose in the small intestine lead to osmotic trapping 
of water and the osmotic load in the colon is increased about 
eightfold by fermentation of lactose to SCFA.13 14 Diarrhoea will 
result if the respective load of lactose exceeds the capacity of the 
colonic microbiota for fermentation or the SCFA load exceeds 
the colon capacity for resorption.15
The likelihood of developing symptoms after lactose ingestion 
is multifactorial (figure 3). Extrinsic factors include the amount 
of lactose ingested and whether dairy products are ingested with 
other foods that affect intestinal transit and the rate of lactose 
delivery to the colon. Intrinsic factors include expression of 
lactase at the brush border of the small intestine, history of GI 
disorders or abdominal surgery and the composition of the intes-
tinal microbiome. When incubated in vitro with lactose, faecal 
samples from lactose-intolerant subjects mediated faster and 
higher production of SCFA than samples from lactose-tolerant 
subjects.16 17 However, an impact of SCFA on symptoms has not 
been directly demonstrated in humans. Further, in the anaer-
obic environment of the intestinal tract, generation of reducing 
equivalents result in rapid hydrogen production, and in several 
clinical studies, the amount of gas production correlated with the 
presence and severity of intestinal symptoms.18 19 Other patient 
factors not directly related to lactose digestion are also associ-
ated with LI. These include the presence of anxiety disorders, 
high levels of psychosocial stress and the presence of functional 
GI disorders such as IBS (figures 3 and 4).
Products of lactose fermentation may also trigger extra-intes-
tinal symptoms. A recent review of results from >2000 patients 
with a clinical diagnosis of functional GI disorders, reported a 
high frequency of neurological symptoms such as tiredness and 
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Figure 2 Worldwide prevalence of lactose malabsorption. Online supplement 1 breaks down the the evidence base in terms of the investigative 
modality used to acquire the epidemiological information (eg, genetic test and breath test). Online supplement 2 provides the complete reference list.
Figure 3 Schematic model of the pathogenesis of lactose intolerance 
symptoms. In a given population, a fraction of individuals will have 
digestive dysfunction resulting in lactose malabsorption. Within 
this population, individuals with anxiety disorders or GI disease 
that increase visceral sensitivity are more susceptible to the lactose 
challenge. In this model, the risk of developing symptoms increases with 
lactose dose, severity of digestive dysfunction (lactose malabsorption) 
and visceral sensitivity. This model of disease is not restricted to 
lactose but is likely to be shared by other FODMAPs, fermentable 
oligosaccharides, disaccharides and monosaccharides and polyols.
headache after lactose or fructose ingestion.20 However, it is 
uncertain whether the occurrence of neurological symptoms was 
caused by LM, because these patients have a high prevalence of 
nonspecific somatic complaints21, there was no placebo control, 
no statistical relationship between H2 production and symptoms 
was present and no mechanistic explanation was provided.20
ePIdemIoLogy
A recent meta-analysis estimated the prevalence of LM world-
wide at 68% with higher rates reported for genetic tests than 
hydrogen breath tests (HBTs).22 LM is lowest in Nordic coun-
tries (<5% in Denmark) and highest in Korean and Han Chinese 
populations (approaches 100%). Large variations in LM are seen 
on a regional level (figure 2),22 reflecting the underlying genetic 
heritage and prevalence of primary LD in these populations. 
Testing for LI is more complex and would require standardised 
hydrogen breath testing in large, carefully selected populations 
and, for this reason, the prevalence of LI is unknown.
geneTICS
In the Caucasian population, lactase persistence (LP) is due to 
a gain-of-function mutation 13.9 kb upstream of the lactase 
gene (LCT-13’910:C→T, ‘‘T’ for tolerance’) on chromosome 2. 
This single nucleotide polymorphism (SNP) is far upstream of 
the protein forming unit within the intron of an unrelated gene 
(figure 5A).23 This mutation creates a new binding site for the 
transcription factor that promotes persistent lactase expression 
after infancy.24
Genetic LP is considered a dominant genotype, and only indi-
viduals with two LCT-13’910:C alleles should be considered to 
have LNP. However, heterozygotes with LCT-13’910:CT geno-
type may have higher H2 levels in the HBT than LCT-13’910:TT 
individuals.25 This intermediate phenotype might be relevant 
during nutritional challenges or intestinal diseases. By contrast, 
epigenetic regulation of the lactase gene appears to be critical. 
Methylation patterns in the region of the LCT-13’910:C/T poly-
morphism in small intestinal enterocytes strongly differ depen-
dent on the genotype, from >80% modification with the LNP 
genotype to 20% with the LP genotype (figure 5B). It has also 
been shown that LCT promotor methylation is low after birth 
but increases in childhood in the presence of LCT-13’910:C but 
not LCT-13’910:T.26 Thus, LNP is a good example of a condition 
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Figure 4 Mechanistic model of lactose digestion in patients with lactase persistence and lactase deficiency illustrating the relationship between 
lactose malabsorption, visceral sensitivity and symptoms.
Figure 5 Genetics of lactose malabsorption. (A) Organisation of the lactase genetic locus on chromosome 2. The positions of the lactase gene 
(LCT) and the neighbouring genes aspartyl-tRNA synthetase (DARS), minichromosome maintenance complex component 6 (MCM6) and UBX 
domain-containing protein 4 (UBXN4) are indicated. Polymorphisms relevant for lactose malabsorption are located within intron 13 of the MCM6 
gene, upstream of the lactase gene. (B) Differential levels of methylation of intron 13 of MCM6 and the LCT gene in individuals with genetic lactose 
malabsorption (LCT −13910:C/C), lactose tolerance (LCT −13910:T/T) and the clinically silent, physiologically intermediate genotype LCT −13910:C/T. 
Hypermethylation (red colour) results in genetic silencing of the respective gene. (Source: From Labrie et al26).
in which DNA sequence variations set the stage for age-depen-
dent methylation which later results in a clinical phenotype, a 
mechanism that might be applicable also to complex diseases.27
The LCT-13’910:T SNP associated with LP in Europe and 
many near Asian regions resides on the same haplotype, indi-
cating rapid spread of a single mutation.28 The mutation appears 
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Table 3 Genetic variations affecting lactase persistence and LM1
mutation associated 
with lactase persistence geographic region SnP
LCT −13’910:T* Northern Europe rs4988235
LCT −13’915:G Middle East rs41380347
LCT −13’907:G Ethiopia and Sudan rs41525747
LCT −14’009:G Ethiopia and Sudan rs820486563
LCT −14’010:C Kenya, Tanzania and South Africa rs145946881
*This mutation is in strong linkage disequilibrium with the LCT −22’018-A 
mutation. Mechanistic evidence indicates that the −13’910 mutation is responsible 
for lactase persistence.
LM,  lactose malabsorption;  SNP,  single nucleotide polymorphism. 
Source: Adapted from Segurel and Bon 1
in prehistoric skeletons for the first time approximately 10 500 
years ago in Anatolia with spread to Europe and Northern Africa 
over time in line with domestication of animals. In Africa and the 
Middle East, different mutations in the same genetic region are 
responsible for LP1 29 (table 3), indicating convergent evolution.
There is convincing genetic evidence for a strong selection 
pressure for LP. In a whole genome analysis of skeletons orig-
inating between 6500 and 300 BC, the LCT-13’910:T allele 
showed increasing prevalence over time.30 LP provided an advan-
tage of up to 4%–5% per generation, which is one of the largest 
selection pressures observed for any gene in recent human evolu-
tion and is in the same order of magnitude as resistance genes 
for malaria (4%–9%), skin pigmentation in Europeans (3%) and 
genes associated with hypoxia response in Tibetan populations 
at high altitude.1
The ability to digest lactose after infancy made milk a source of 
nutrition (calories, protein) and clean water accessible to adults. 
This is likely to have been critical in periods of famine. However, 
why LP increased fitness to such a high degree is unclear since 
many individuals with LM can consume 250 mL of milk without 
developing symptoms, and processing of milk to yoghurt, cheese 
or butter decreases the advantage of LP further.31 Further, the ‘cost’ 
of LNP with generally mild abdominal symptoms seems modest 
and individuals with LNP may even benefit from milk consump-
tion due to prebiotic activity of lactose on the colonic microbiota.1 
Increased intake of vitamin D from milk could also provide a selec-
tive advantage, especially in Northern Europe with a high risk of 
vitamin D deficiency due to low ultraviolet exposure.3 32
Taken together, impressive selection pressure took place at 
the lactase genetic locus after the uptake of pastoralist farming, 
favouring LP in many regions worldwide; however, the specific 
advantage of milk consumption that increased survival and 
whether these are present only during times of dietary or health 
stress or continuously remain unclear.
SeCondaRy LaCToSe maLaBSoRPTIon
Secondary LM refers to the development of LM in individuals 
who are potentially able to digest lactose (ie, LP individuals).33 34 
Lactase is situated at the tip of intestinal villi and thus vulner-
able to intestinal injury, especially since new immature entero-
cytes are lactase deficient.6 As a consequence, secondary LM can 
complicate GI conditions including infectious gastroenteritis, 
IBD, coeliac disease and systemic sclerosis (SSc).
The incidence of secondary LM, which is often transitory, 
caused by infectious gastroenteritis is increased and can be 
clinically relevant,35 especially in infants for whom milk is the 
staple food. In a paediatric study (mean age 12 months) with 
126 patients with rotavirus infection and 62 controls with 
rotavirus negative diarrhoea, LM was more frequent in the 
former group (60% vs 49%, p=0.002).36 Similarly, in adult 
patients with chronic diarrhoea after kidney transplantation, 
those with norovirus colonisation had a much higher risk for 
LM than a control group (100% vs 12.5%).37 A systematic 
review concluded that exclusion of lactose would reduce the 
duration of acute diarrhoea in children by up to a day and 
reduce ‘treatment failure’ (RR: 0.5, 95% CI: 0.4 to 0.7), vari-
ously described in studies as requirement for unscheduled 
intravenous fluid injection or persistent stool weight >30 g/ 
kg after 3 days.38
Similar but more persistent results are seen in IBD. In a 
meta-analysis, the overall OR for LM in patients with IBD was 
1.6 (95% CI: 1.0 to 2.6, p=0.048), being highest in Crohn’s 
disease (CD) affecting the small bowel.39 In line with this 
observation, a paediatric study showed reduced lactase expres-
sion in CD patients with the risk of LD correlated with villous 
atrophy.39 40 High prevalence of secondary LM has also been 
reported in other conditions that affect the mucosal integrity 
or function of the small bowel. Patients with a new diagnosis 
of coeliac disease often have a positive lactose HBT; however, 
many recover the ability to digest lactose after 6–12 months 
on a gluten-free diet.41Patients with SSc also have a high preva-
lence of LM on breath testing, a finding that is associated with 
more advanced disease.42 Secondary LD may complicate envi-
ronmental enteric dysfunction (EED), a condition that affects 
mainly children in an environment with low resources, poor 
hygiene and poor nutrition. EED is characterised by intestinal 
atrophy and dysbiosis associated with enzyme deficiencies, 
malabsorption and malnutrition.43
LaCToSe maLaBSoRPTIon and The mICRoBIoTa
The human body harbours approximately 40 trillion bacteria 
with approximately 99% of the microbiome contained within in 
the human colon. Fermentation of lactose by saccharolytic (‘sugar 
digesting’) bacteria in individuals with LM can cause abdominal 
symptoms (figures 1 and 4). However, this process also has bene-
fits. SCFA and other products of fermentation are required for 
colonic health and liberate additional calories from otherwise 
indigestible carbohydrates. Moreover, the intestinal microbiota 
adapts to facilitate intake of dairy products. As a result, although 
lactase expression is not upregulated by lactose ingestion, regular 
consumption of lactose appears to reduce breath hydrogen 
excretion and reduced lactose intolerant symptoms.44 Both in 
vitro and in vivo studies demonstrate increases in Bifidobacteria 
and/or Lactobacilli that are considered to be healthy components 
of the microbiome.45 46 In a large study of healthy Japanese, the 
abundance of Bifidobacteria correlated positively with dietary 
dairy intake.47 As this population is 90%–100% LNP, this could 
reflect the effect of regular lactose intake on the microbiota; 
however, the reverse cannot be excluded .
Recent data point to interactions between human genes and 
the microbiota. In association studies between human genetic 
variations and the microbiota, to date, the association most 
consistently described is that between the LCT-13’910:C/T 
SNP and the abundance of Bifidobacterium.48–50 Such interac-
tions might have practical implications because SCFAs produced 
by microbial fermentation of lactose are involved in immune 
regulation,51 glucose and lipid homeostasis,52 colonocyte differ-
entiation53 with implications for homeostasis and gut-brain 
modulation.54 Taken together, some experts suggest that LNP 
subjects may have ‘more to gain than to lose’ by consumption of 
small amounts of lactose-containing foods.55
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Table 4 Brief characterisation of the diagnostic tests available for lactose malabsorption
hydrogen breath test
Lactose tolerance 
test duodenal lactase activity
Serum gaxilose or urine 
galactose test genetic test
Lactose challenge Yes Yes No Yes (gaxilose) No
Assessment of 
symptoms and LI
Yes/possible Yes/possible No/not possible No/not possible No/not possible
Test principle Detection of H2 in expiratory air Increase in plasma 
glucose after lactose 
challenge
Lactase enzymatic activity 
in duodenal biopsy
Detection of D-xylose in serum 
or Galactose in urine after 
cleavage of orally administered 
4-galactosylxylose (gaxilose) by 
lactase
Detection of −13910 C/T 
polymorphism
Detection of 
secondary LM
Yes Yes Yes Yes No
Costs Low Lowest High (if costs for endoscopy 
are included)
Intermediate High
Limitations False-negative tests by H2-non- 
producer. False-positive tests 
with SIBO, rapid transit, altered 
bowel anatomy
Disorders of glucose 
metabolism, altered 
bowel anatomy
Patchy expression of lactase Variable test performance in 
literature. False-positive tests 
with SIBO, rapid transit and other 
conditions
False negative in 
the presence of atypical 
mutations (relevant in non-
Caucasian populations)
Best use Test of choice to assess LM and 
symptoms (LI)
Low resource setting, 
LM epidemiology
If gastroscopy is performed 
for other reasons
To be determined LD/LNP epidemiology
LD, lactase deficiency; LI, lactose intolerance; LM, lactose malabsorption; LNP, lactase non-persistence; SIBO, small intestinal bacterial overgrowth.
LaCToSe InToLeRanCe and IBS
The relationship of LI and IBS has been extensively studied in 
a South Chinese population with near 100% LNP on genetic 
testing. A double-blinded, randomised, cross-over comparison 
of lactose tolerance at 10, 20 and 40 g lactose was performed 
in IBS patients with diarrhoea (IBS-D) and healthy controls.56 
There was a very strong correlation between the appearance of 
hydrogen gas in the breath and reports of bloating, pain and 
other symptoms in patients with lactose intolerance. However, 
the correlation between the amount of hydrogen gas in the 
breath and the severity of symptoms was much weaker. Consis-
tent with preliminary findings in a European population,57 a key 
observation was that the risk of symptoms and the severity of 
symptoms were greatly increased in IBS patients, especially at 
the low to moderate doses found in the normal diet. It is well 
known that many patients with functional GI disorders have 
psychological comorbidity and are hypersensitive to dietary and 
physical stimuli that affect the digestive tract. 21 58 Further work 
demonstrated that anxiety, visceral hypersensitivity (defined by 
rectal barostat) and high levels of gas production on breath tests 
all increased the severity of abdominal symptoms after ingestion 
of 20 g lactose.19 Moreover, mucosal biopsies from the ileum and 
colon showed increased numbers of mast cells and intraepithe-
lial lymphocytes in lactose-sensitive patients and showed that the 
release of inflammatory cytokines (eg, tumour necrosis factor) 
after lactose intake was higher in this group than controls .59
These observations are similar to those in post-infective IBS58 
and provide insight into the pathophysiological basis not only of 
food intolerance but, more generally, functional GI symptoms. 
IBS is a heterogenous condition; however, symptoms related to 
intake of food items with poorly absorbed, fermentable carbohy-
drates such as lactose are reported by up to 70% of patients with 
this diagnosis.60–62 Patients with LI and IBS complain of similar 
symptoms, have high rates of psychological comorbidity and 
markers of an activated innate mucosal immune system. More-
over, both respond to similar dietary interventions (see below). 
Together, this evidence suggests a common pathological basis in 
which a susceptible individual with a sensitive (‘irritable’) bowel 
develops symptoms when exposed even to a modest stimulus, 
such as low–moderate doses of lactose (figure 3).33
LaCToSe InToLeRanCe and quaLITy oF LIFe
Like other functional GI disorders, LI is not a trivial condition 
but has a negative impact on quality of life and nutrition. Anxiety 
increases the risk of symptoms (‘intolerance’) after lactose inges-
tion, but the fear that food will trigger bloating, pain and diar-
rhoea is also a cause of anxiety. Indeed, in studies, not only 
patients with LI but also those with self-diagnosed LI who do not 
have the condition describe a lower quality of life than individ-
uals without concerns about food intolerance.61 62 This anxiety 
generalises to other foods, and patients with LI often describe 
intolerance to a range of products, especially those known to 
cause bloating (eg, legumes and dried fruit).62 As a result, indi-
viduals might adopt a restrictive diet that could impact on health 
in a variety of ways.60 62 63 In severe cases, this form of behaviour 
is termed avoidant/restrictive food intake disorder by DSM-5, a 
form of eating disorder that is associated with weight loss but 
not with body dysmorphia.64
TeSTIng FoR LaCToSe maLaBSoRPTIon and 
InToLeRanCe
Five tests of lactose digestion are available, each of which investi-
gates different aspects of the process and has specific advantages 
and disadvantages (table 4).
Genetic tests apply real-time PCR or sequencing on DNA 
extracted from a venous blood or buccal swab sample and 
are most appropriate in epidemiological studies. In Cauca-
sians, LP is nearly uniformly mediated by the LCT-13910:C/T 
polymorphism, and genetic testing can detect genetic LNP. 
However, the genetic situation is more complex in patients 
with African or Asian heritage (table 3) and genetic tests 
are currently not advocated in these populations for clinical 
purposes. Importantly, secondary LM will not be detected by 
genetic tests.
Tests for lactase enzymatic activities on intestinal biopsies 
will detect primary and secondary LM. While an endoscopy 
with sedation is not indicated for this purpose, this test can 
be performed if endoscopy is indicated for other reasons. It 
should be noted that lactase activity is patchy and more than a 
single biopsy may be required for optimal test accuracy.65
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Figure 6 Symptoms in individuals with lactose malabsorption depend 
on lactose dose and visceral hypersensitivity. A population of Chinese 
individuals (100% primary lactase non-persistence) including HV with 
no history of abdominal symptoms and individuals with IBS-D was 
tested three times with different lactose dosages (10, 20 and  40 g) in 
a blinded fashion. The likelihood of a clinically positive HBT was higher 
in individuals with IBS-D for the low and the intermediate lactose dose. 
HBT,  hydrogen breath test; HV, healthy volunteers; IBS-D,  diarrhoea-
predominant  irritable bowel syndrome.  (Source: Adapted from Yang et 
al.56)
Figure 7 Results of a hydrogen breath test of an individual with lactose intolerance with simultaneous assessment symptoms and H2 levels, 
indicating lactose fermentation by the microbiota. An H2 increase by ≥20 ppm over baseline indicates lactose malabsorption. When 
13C-labelled 
lactose is administered, 13CO2 levels indicate absorption and metabolisation of 
13C-labelled lactose by the subject. Patient reports of abdominal 
symptoms subsequent to increases in these markers is diagnostic of lactose intolerance.
The lactose HBT measures the excretion of hydrogen in 
expiratory air after an oral challenge with a standard dose of 
lactose. As hydrogen is not produced by mammalian enzymes, 
its presence indicates contact of the sugar with bacteria 
indicating LM, although small intestinal bacterial over-
growth cannot be excluded. In clinical practice, an interme-
diate lactose dosage of 20–25 g may be optimal.56 66 Smaller 
amounts of lactose lack sensitivity for LM. Larger amounts 
used in epidemiological studies (eg, 40–50 g, figure 6) induce 
symptoms even in healthy individuals with LM that tolerate 
the amount of lactose present in normal diets (see below).56 
A baseline H2 value <20 ppm is a requirement for a reliable 
test and an increase ≥20 ppm within 3 hours is diagnostic 
of LM.66 Reducing observation time impairs sensitivity; 
however, only four measurements (0, 90, 120, 180 min) are 
required for valid results.67 An H2-non-producing microbiota 
can lead to false-negative HBT. In some of these individ-
uals, methanogenic bacteria (eg, Methanobrevibacter smithii) 
convert hydrogen to methane (CH4) in a 4:1 ratio resulting 
in lower H2 excretion and a lower fraction of positive tests.
66 
Simultaneous assessment of methane can partially overcome 
this limitation. Therefore, even though the increase in CH4 
is often low (<20 ppm) and not correlated to symptoms, 
combined H2/CH4-measurements are recommended by some 
authors.66 68 A more reliable approach involves the use of 
13C-lactose with simultaneous breath measurements of 13CO2 
as a marker of lactose digestion and H2 as a marker of LM 
(figure 7); however, this technique is not available outside 
specialist centers.69
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Figure 8 Management of lactose malabsorption and lactose 
intolerance. FODMAPs, fermentable oligosaccharides, disaccharides and 
monosaccharides and polyols.
The lactose tolerance test measures glucose in plasma at 
different times (e.g. 0, 30, 60, 120 min) after ingestion of 50 g 
lactose. Although the test does not require complex or expen-
sive equipment, its invasive nature (multiple blood samples) 
limits its utility. Use of capillary blood measurements with 
portable glucose metres makes the test less invasive but does 
not offer the same diagnostic accuracy as measurements in 
venous blood.70
The gaxilose test involves the administration of the lactase 
substrate gaxilose (4-galactosylxylose) with measurement of 
D-xylose in urine or blood. Conceptually, gaxilose measure-
ments are ideal for assessment of intestinal lactase since activity 
over the entire small intestine is measured.71 In a manufac-
turer-sponsored trial, the diagnostic accuracy of gaxilose tests 
(0.93) was higher than HBT (0.85) or lactose tolerance tests 
(0.79) in comparison to duodenal biopsies.71 However, this was 
not confirmed in an independent study when the genetic test 
(LCT-13’910:C/T) was used as reference.72
TeSTIng FoR LaCToSe InToLeRanCe
The major limitation of the genetic, enzymatic and gaxilose tests 
is that LM is common in healthy individuals, and a positive test 
does not confirm that symptoms are caused by this condition. 
For this reason, in our practice, HBT is the method of choice 
because reasonably reliable information about digestive function 
and patient symptoms are obtained.
The diagnosis of LI requires appropriate testing of symptoms 
using validated questionnaires designed for the purpose.73 A 
National Institute of Health consensus conference defined LI 
as ‘the onset of GI symptoms following a blinded, single-dose 
challenge of ingested lactose by an individual with LM, which 
are not observed when the person ingests an indistinguish-
able placebo’,74 thus supporting the case for blinded testing of 
symptoms. Although rarely performed outside clinical studies, 
blinded testing might be useful since in clinical practice, the 
correlation between self-reported symptoms of LI and objec-
tive findings on tests for lactose digestion is low.62 Indeed, 
among individuals referred for HBT, about half of those with 
normal lactose digestion report abdominal discomfort after 
an unblinded lactose challenge.69 Further, intolerance to dairy 
products is reported by 20% of all individuals75 and up to 
70% of IBS patients in European populations with low rates 
of genetic LNP.60
A ‘blinded multiple dose challenge’ would provide clarity not 
only regarding lactose digestion but also identify the amount of 
lactose that individuals could ‘safely’ consume (figure 6).56 More-
over, in subjects with known LNP, these could be performed at 
patients’ homes with a negative control, low and intermediate 
lactose challenge (eg, 12.5 and 25 g, corresponding to 250 and 
500 mL milk, respectively).34 This could help educate patients 
because, in real life, it is self-reported intolerance and not the 
objective results of testing that best predicts food choices.62 
However, to the best of our knowledge, blinded home-based 
testing has not been tested in routine clinical practice. The need 
for a well-accepted, practical and cost-effective investigation of 
food intolerance that predicts the outcome of dietary therapy is 
a key clinical challenge in functional GI disorders. The ability to 
predict the outcome of dietary therapy would be the measure for 
an appropriate symptom assessment.
TheRaPeuTIC oPTIonS
Therapy of lactose intolerance aims to improve patient symp-
toms and to avoid risk for undernutrition or malnutrition in 
the long term (figure 8). A diet low in lactose is typically recom-
mended and this is supported by common sense and clinical 
evidence .56 However, in contrast to the management of sprue 
or food allergies, a strict lactose-free diet is not required since 
patients with LI often tolerate up to 250 mL milk (12 g lactose) 
without symptoms and more when consumed with food.31
Improved lactose tolerance by manipulating the colonic 
microbiota could also be achieved by ingestion of prebiotics.44 
A randomised placebo-controlled study in 85 LI patients 
reported that regular ingestion of short-chain galacto-oligosac-
charides (GOS, RP-G28) tended to reduce H2 production and 
improve abdominal pain during lactose HBT. After 1 month, 
30% of GOS-treated patients versus 6% of placebo-treated 
patients considered themselves lactose tolerant.76 Microbiolog-
ical workup revealed a transient increase in lactose fermenting 
Bifidobacterium spp. on GOS treatment and a negative correla-
tion between Bifidobacterium levels and abdominal pain, and 
re-introduction of milk prompted a further shift in bacterial 
composition, including an increase in the genus Roseburia.77
Lactose-free dairy products in which lactase is added to milk 
are widely available and considered safe, although allergic reac-
tions have been reported.78 Lactase treatment of milk products 
also reduces crystallisation of lactose, increasing sweetness and 
fermentation for production of yoghurt.79 However, residual 
side proteolytic activity of lactase can degenerate casein and 
impair taste, especially after long storage.80
Lactase supplementation by tablets improves both lactose 
digestion (reduced H2 production) and symptoms
81 82 although 
the effects are modest (eg, 18% with overall reduction of symp-
toms82). An alternative approach is to ingest probiotics such 
as Lactobacillus spp., Bifidobacterium longum or Bifidobacte-
rium animalis that produce lactase in the gut. A recent systematic 
review of this treatment option confirmed an overall positive 
effect; however, the effect size was not consistently better than 
lactase supplementation and study quality was poor.83
In many clinical studies, only a minority of patients with LI on 
HBT report satisfactory improvement in symptoms after treat-
ment to reduce intake of dairy products or supplement lactase. 
Moreover, it remains unclear, to what extent the therapy itself 
and conditioning of patient expectations contribute to outcome. 
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Lack of improvement can also be due to the presence of func-
tional bowel disorders, which are present in many patients 
referred for investigation. These patients are sensitive to various 
nutrients, mechanical and chemical stimuli and, therefore, rarely 
respond to restriction of dairy products alone.84
IBS patients develop symptoms after ingestion of a range of 
poorly absorbed, fermentable carbohydrates (fermentable oligo-
saccharides , disaccharides and monosaccharides and polyols 
(FODMAPs)) that includes but is not restricted to lactose even 
in LM patients.85 A low-FODMAP diet improves abdominal 
symptoms in 50%–80% of IBS patients.86 87 This dietary therapy 
requires commitment from the patient and is best delivered by 
professional dietician. Identification of factors predicting dietary 
outcome would improve compliance and cost-effectiveness of 
this intervention; however, in a large clinical study neither clin-
ical presentation nor HBT results (high dose lactose 50 g or fruc-
tose 35 g) predicted response to the low-FODMAP diet.87 The 
response to an intermediate dose of a representative, non-ab-
sorbable FODMAP (eg, lactulose 20 g) that rarely c symptoms in 
health, but often induces bloating, abdominal pain and diarrhea 
in FGID patients may improve the ability of HBT to identify 
individuals that respond to this dietary intervention. Alterna-
tively, bioassays to identify saccharolytic bacteria and/or fermen-
tation capacity in faecal samples might be developed that predict 
outcome of lactose (or FODMAP) restriction in patients.88
Long-TeRm ComPLICaTIonS oF LaCToSe InToLeRanCe
Considering the objective effects of genetic LD on intestinal 
microbiota and recent human evolution (see above), LM and LI 
are likely to have a relevant impact on nutrition. Dairy prod-
ucts are valuable sources of protein, calcium and vitamin D.89 
However, these nutrients can also be acquired from other food 
sources.
The relationship between lactose tolerance and height has been 
demonstrated, although some of this effect could be explained by 
population stratification.90 Daily milk consumption of 245 mL is 
associated with increased body height (0.39 cm, 95% CI: 0.29 
to 0.48).90 Similarly, milk intake and LP have been linked with 
higher body mass index (BMI) in some studies.91
Effects of nutrition on health are difficult to address in inter-
ventional studies due to need for long-term follow-up, costs 
and limited compliance in patients. However, since LM in 
Caucasians is a monogenic condition (LCT −13’910C geno-
type), this question can be addressed by applying a Mendelian 
randomisation approach that limits confounding by social, 
environmental or behavioural factors. A recent study using 
this methodology confirmed higher milk consumption in indi-
viduals with genetic LP and this was associated with vitamin D 
levels which were 2.3-fold (OR: 1.6–3.4) lower in individuals 
with LCT-13’910:CC and 1.5-fold lower in LCT-13’910:CT 
compared with LCT-13’910:TT.92 Vitamin D is important for 
bone mineralisation and a separate meta-analysis showed a 
higher bone mineral density and a lower risk of fractures for 
TT versus CT/CC (OR: 0.81, 95% CI: 0.7 to 0.94, p=0.005).93 
However, this finding was not confirmed in a European study 
that applied a similar study design.91
Results regarding other effects of milk consumption such as 
cardiovascular health and cancer are controversial.94 In a large 
Swedish study, individuals with high consumption of non-fer-
mented milk and other dairy products had a higher all-cause 
mortality (HR: 1.32, 95% CI: 1.18 to 1.48); however, these 
results were not robust in the subgroup for which a Mende-
lian randomisation study could be performed.95 Some of these 
findings might be explained by an effect of LP on BMI (see 
above). In any case, these conflicting results are not surprising 
considering the complexity of the diet with regards to avail-
ability of lactose-free milk, intake of calcium, vitamin D, satu-
rated fats, cholesterol, proteins and calories. Moreover, other 
genetic markers for lipid metabolism and polymorphisms of 
the vitamin D receptor might also impact on health.94 Addi-
tional studies with new approaches accounting for multiple 
nutrients and multiple genetic markers are needed to clarify 
the relationship of milk consumption, LM and long-term 
outcomes.
ouTLook
Primary genetic LP and non-persistence are common in healthy 
humans; however, ingestion of milk by individuals with LD leads 
to LM and, in susceptible patients, to symptoms of lactose intol-
erance. Diagnosis is based on detection either of the genetic muta-
tion, loss of lactase activity in the enteric mucosa or evidence of 
malabsorption by breath tests. However, the association between 
self-reported LI, objective findings of tests and clinical outcome 
of dietary intervention is variable. Recent studies have provided 
important new insight into the complex relationship between 
LD, LM and symptom generation. This work has shed light on 
the important issue of food intolerance as a cause of symptoms 
in IBS and other functional GI disorders.
The development of a well-accepted, practical and cost-effec-
tive investigation of food intolerance that predicts the outcome 
of dietary therapy is one of the biggest clinical challenges in the 
field of functional GI disorders. Understanding the biological 
mechanism for food intolerance will help clinicians make a defin-
itive diagnosis and guide rational dietary and medical manage-
ment. Ongoing studies will provide high-quality evidence to 
document the clinical outcome, cost-effectiveness and long-term 
effects of these strategies.
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